

# Giulia Taraboletti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1811418/publications.pdf>

Version: 2024-02-01

82  
papers

5,737  
citations

61984

43  
h-index

76900

74  
g-index

86  
all docs

86  
docs citations

86  
times ranked

7150  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Shedding of the Matrix Metalloproteinases MMP-2, MMP-9, and MT1-MMP as Membrane Vesicle-Associated Components by Endothelial Cells. <i>American Journal of Pathology</i> , 2002, 160, 673-680.   | 3.8  | 502       |
| 2  | Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor.. <i>Journal of Cell Biology</i> , 1990, 111, 765-772.   | 5.2  | 392       |
| 3  | Endothelin-1 Induces an Angiogenic Phenotype in Cultured Endothelial Cells and Stimulates Neovascularization In Vivo. <i>American Journal of Pathology</i> , 2000, 157, 1703-1711.   | 3.8  | 322       |
| 4  | Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. <i>Cancer Research</i> , 2003, 63, 5224-9.                                     | 0.9  | 241       |
| 5  | Current understanding of the thrombospondin-1 interactome. <i>Matrix Biology</i> , 2014, 37, 83-91.  | 3.6  | 228       |
| 6  | Inhibition of Angiogenesis and Murine Hemangioma Growth by Batimastat, a Synthetic Inhibitor of Matrix Metalloproteinases. <i>Journal of the National Cancer Institute</i> , 1995, 87, 293-298.  | 6.3  | 220       |
| 7  | Bioavailability of VEGF in Tumor-Shed Vesicles Depends on Vesicle Burst Induced by Acidic pH. <i>Neoplasia</i> , 2006, 8, 96-103.  | 5.3  | 168       |
| 8  | Induction of haptotactic migration of melanoma cells by neutrophil activating protein/interleukin-8. <i>Biochemical and Biophysical Research Communications</i> , 1990, 169, 165-170.  | 2.1  | 166       |
| 9  | The heparin binding 25 kDa fragment of thrombospondinâ€1 promotes angiogenesis and modulates gelatinase and TIMPâ€2 production in endothelial cells. <i>FASEB Journal</i> , 2000, 14, 1674-1676.   | 0.5  | 146       |
| 10 | Cytokine-induced pseudopodial protrusion is coupled to tumour cell migration. <i>Nature</i> , 1987, 329, 261-263.  | 27.8 | 145       |
| 11 | Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4. <i>Leukemia</i> , 2003, 17, 52-59.                        | 7.2  | 142       |
| 12 | Cathepsin B Mediates the pH-Dependent Proinvasive Activity of Tumor-Shed Microvesicles. <i>Neoplasia</i> , 2008, 10, 481-488.  | 5.3  | 137       |
| 13 | Membrane fluidity affects tumor-cell motility, invasion and lung-colonizing potential. <i>International Journal of Cancer</i> , 1989, 44, 707-713.   | 5.1  | 99        |
| 14 | Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. <i>Cancer Research</i> , 2003, 63, 1534-7.   | 0.9  | 94        |
| 15 | Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2. <i>Blood</i> , 2003, 102, 4399-4406.   | 1.4  | 93        |
| 16 | Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development. <i>European Journal of Cancer</i> , 2006, 42, 2821-2832.   | 2.8  | 90        |
| 17 | Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. <i>European Journal of Cancer</i> , 2003, 39, 1948-1956. | 2.8  | 87        |
| 18 | Modelling approaches for angiogenesis. <i>European Journal of Cancer</i> , 2004, 40, 881-889.  | 2.8  | 85        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Antiangiogenic activity of aplidine, a new agent of marine origin. <i>British Journal of Cancer</i> , 2004, 90, 2418-2424.  | 6.4 | 82        |
| 20 | Modulation of Laminin Receptor Expression by Estrogen and Progestins in Human Breast Cancer Cell Lines. <i>Journal of the National Cancer Institute</i> , 1989, 81, 781-789.  | 6.3 | 81        |
| 21 | Non-peptidic Thrombospondin-1 Mimics as Fibroblast Growth Factor-2 Inhibitors. <i>Journal of Biological Chemistry</i> , 2010, 285, 8733-8742.   | 3.4 | 70        |
| 22 | Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain. <i>International Journal of Biochemistry and Cell Biology</i> , 2008, 40, 700-709.                          | 2.8 | 67        |
| 23 | Proliferative and migratory responses of murine microvascular endothelial cells to granulocyte-colony-stimulating factor. <i>Journal of Cellular Physiology</i> , 1993, 155, 89-95.                                     | 4.1 | 66        |
| 24 | Vascular Endothelial Growth Factor Stimulates Organ-Specific Host Matrix Metalloproteinase-9 Expression and Ovarian Cancer Invasion. <i>Molecular Cancer Research</i> , 2008, 6, 525-534.                               | 3.4 | 65        |
| 25 | Vascular Disrupting Activity of Tubulin-Binding 1,5-Diaryl-1 <i>H</i> -imidazoles. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 7906-7910.   | 6.4 | 65        |
| 26 | Gorham-Stout Syndrome: A Monocyte-Mediated Cytokine Propelled Disease. <i>Journal of Bone and Mineral Research</i> , 2005, 21, 207-218.   | 2.8 | 64        |
| 27 | Antiangiogenic and antivascular therapy for cancer. <i>Current Opinion in Pharmacology</i> , 2001, 1, 378-384.  | 3.5 | 62        |
| 28 | Tumor-derived chemotactic factor(S) from human ovarian carcinoma: Evidence for a role in the regulation of macrophage content of neoplastic tissues. <i>International Journal of Cancer</i> , 1985, 36, 167-173.        | 5.1 | 59        |
| 29 | ADAMDEC1 Maintains a Growth Factor Signaling Loop in Cancer Stem Cells. <i>Cancer Discovery</i> , 2019, 9, 1574-1589.   | 9.4 | 59        |
| 30 | Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors. <i>Oncotarget</i> , 2010, 1, 662-673.   | 1.8 | 57        |
| 31 | Vascular Endothelial Growth Factor C Promotes Ovarian Carcinoma Progression through Paracrine and Autocrine Mechanisms. <i>American Journal of Pathology</i> , 2014, 184, 1050-1061.                                    | 3.8 | 56        |
| 32 | Soluble stroma-related biomarkers of pancreatic cancer. <i>EMBO Molecular Medicine</i> , 2018, 10, .  | 6.9 | 56        |
| 33 | Reduced Expression of the ROCK Inhibitor Rnd3 Is Associated with Increased Invasiveness and Metastatic Potential in Mesenchymal Tumor Cells. <i>PLoS ONE</i> , 2010, 5, e14154.   | 2.5 | 54        |
| 34 | Thrombospondin-1 promotes mesenchymal stromal cell functions via TGF $\beta$ <sup>2</sup> and in cooperation with PDGF. <i>Matrix Biology</i> , 2016, 55, 106-116.  | 3.6 | 52        |
| 35 | p73 overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis. <i>Oncogene</i> , 2001, 20, 7293-7300.  | 5.9 | 51        |
| 36 | Antiangiogenic activity of trabectedin in myxoid liposarcoma: Involvement of host TIMP $\alpha$ 1 and TIMP $\alpha$ 2 and tumor thrombospondin $\alpha$ 1. <i>International Journal of Cancer</i> , 2015, 136, 721-729. | 5.1 | 50        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative. <i>Clinical Cancer Research</i> , 2002, 8, 1182-8.   | 7.0 | 50        |
| 38 | Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel. <i>British Journal of Cancer</i> , 2007, 97, 888-894.   | 6.4 | 49        |
| 39 | CXCR4 on human endothelial cells can serve as both a mediator of biological responses and as a receptor for HIV-2. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2000, 1500, 227-240.  | 3.8 | 48        |
| 40 | ERK1-2 and p38 MAPK regulate MMP/TIMP balance and function in response to thrombospondin-1 fragments in the microvascular endothelium. <i>Life Sciences</i> , 2004, 74, 2975-2985.   | 4.3 | 48        |
| 41 | Matrigel promotes retinoblastoma cell growth in vitro and in vivo. <i>International Journal of Cancer</i> , 1992, 52, 234-240.   | 5.1 | 46        |
| 42 | Thrombospondin-1 is part of a Slug-independent motility and metastatic program in cutaneous melanoma, in association with VEGFR-1 and FGF-2. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 73-81.  | 3.3 | 45        |
| 43 | Enhancement of Metastatic Potential of Murine and Human Melanoma Cells by Laminin Receptor Peptide G: Attachment of Cancer Cells to Subendothelial Matrix as a Pathway for Hematogenous Metastasis. <i>Journal of the National Cancer Institute</i> , 1993, 85, 235-240. | 6.3 | 44        |
| 44 | Mesothelial cells induce the motility of human ovarian carcinoma cells. , 1999, 80, 303-307.   |     | 44        |
| 45 | Thrombospondin-1 inhibits Kaposi's sarcoma (KS) cell and HIV-1 Tat-induced angiogenesis and is poorly expressed in KS lesions. , 1999, 188, 76-81.   |     | 44        |
| 46 | Posttranscriptional Stimulation of Endothelial Cell Matrix Metalloproteinases 2 and 1 by Endothelioma Cells. <i>Experimental Cell Research</i> , 2000, 258, 384-394.   | 2.6 | 43        |
| 47 | Pentraxin 3 regulates synaptic function by inducing AMPA receptor clustering via ECM remodeling and $\alpha 1$ integrin. <i>EMBO Journal</i> , 2019, 38, .   | 7.8 | 42        |
| 48 | Preclinical development of metalloprotease inhibitors in cancer therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2001, 37, 53-60.   | 4.4 | 41        |
| 49 | Direct and Allosteric Inhibition of the FGF2/HSPGs/FGFR1 Ternary Complex Formation by an Antiangiogenic, Thrombospondin-1-Mimic Small Molecule. <i>PLoS ONE</i> , 2012, 7, e36990.   | 2.5 | 40        |
| 50 | Antiproliferative properties of flavone acetic acid (NSC 347512) (LM 975), a new anticancer agent. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1987, 23, 1529-1535.  | 0.7 | 39        |
| 51 | Expression of the 67 kD Laminin receptor in human ovarian carcinomas as defined by a monoclonal antibody, MLuC5. <i>European Journal of Cancer</i> , 1996, 32, 1598-1602.  | 2.8 | 39        |
| 52 | The Tyrosine Kinase Inhibitor E-3810 Combined with Paclitaxel Inhibits the Growth of Advanced-Stage Triple-Negative Breast Cancer Xenografts. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 131-140.  | 4.1 | 39        |
| 53 | Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 879-887.  | 2.3 | 37        |
| 54 | The calcium-binding type III repeats domain of thrombospondin-2 binds to fibroblast growth factor 2 (FGF2). <i>Angiogenesis</i> , 2019, 22, 133-144.   | 7.2 | 37        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Targeting angiogenesis with compounds from the extracellular matrix. <i>International Journal of Biochemistry and Cell Biology</i> , 2011, 43, 1674-1685.   | 2.8 | 36        |
| 56 | Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors. <i>Oncotarget</i> , 2010, 1, 662-73.  | 1.8 | 33        |
| 57 | Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action. <i>Pharmaceuticals</i> , 2010, 3, 1241-1278.  | 3.8 | 30        |
| 58 | Inhibition of matrix metalloproteinases by overexpression of tissue inhibitor of metalloproteinase-2 inhibits the growth of experimental hemangiomas. <i>International Journal of Cancer</i> , 2001, 91, 241-247.   | 5.1 | 29        |
| 59 | Inhibition of SIRT2 Potentiates the Anti-motility Activity of Taxanes: Implications for Antineoplastic Combination Therapies. <i>Neoplasia</i> , 2012, 14, 846-IN16.  | 5.3 | 28        |
| 60 | Antimetastatic and antiangiogenic activity of trabectedin in cutaneous melanoma. <i>Carcinogenesis</i> , 2019, 40, 303-312.   | 2.8 | 28        |
| 61 | Alternative Vascularization Mechanisms in Tumor Resistance to Therapy. <i>Cancers</i> , 2021, 13, 1912.   | 3.7 | 28        |
| 62 | Thrombospondin-1/HIV-1 Tat protein interaction: modulation of the biological activity of extracellular Tat. <i>FASEB Journal</i> , 2000, 14, 1917-1930.   | 0.5 | 27        |
| 63 | Potential Antagonism of Tubulin-Binding Anticancer Agents in Combination Therapies. <i>Clinical Cancer Research</i> , 2005, 11, 2720-2726.  | 7.0 | 23        |
| 64 | CCN-Based Therapeutic Peptides Modify Pancreatic Ductal Adenocarcinoma Microenvironment and Decrease Tumor Growth in Combination with Chemotherapy. <i>Cells</i> , 2020, 9, 952.  | 4.1 | 23        |
| 65 | Increased Tumorigenicity and Invasiveness of C6 Rat Glioma Cells Transfected with the Human {FC12}a-2,8 Sialyltransferase cDNA. <i>Invasion &amp; Metastasis</i> , 1998, 18, 142-154.   | 0.5 | 22        |
| 66 | Effect of alltrans-retinoic acid (ATRA) on the adhesive and motility properties of acute promyelocytic leukemia cells. , 1997, 70, 72-77.   |     | 21        |
| 67 | Integrating computational and chemical biology tools in the discovery of antiangiogenic small molecule ligands of FGF2 derived from endogenous inhibitors. <i>Scientific Reports</i> , 2016, 6, 23432.  | 3.3 | 20        |
| 68 | Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin. <i>Clinical and Experimental Metastasis</i> , 2015, 32, 647-658. | 3.3 | 17        |
| 69 | Hepatocyte growth factor (HGF) downregulates thrombospondin 1 (TSP-1) expression in thyroid papillary carcinoma cells. <i>Journal of Pathology</i> , 2005, 205, 50-56.  | 4.5 | 15        |
| 70 | Thrombospondin modulates basic fibroblast growth factor activities on endothelial cells. <i>Exs</i> , 1992, 61, 210-213.  | 1.4 | 15        |
| 71 | Tumor-host interaction in the optimization of paclitaxel-based combination therapies with vascular targeting compounds. <i>Cancer and Metastasis Reviews</i> , 2007, 26, 481-488.   | 5.9 | 12        |
| 72 | Molecular Basis of the Antiangiogenic Action of Rosmarinic Acid, a Natural Compound Targeting Fibroblast Growth Factor-2/FGFR Interactions. <i>ChemBioChem</i> , 2021, 22, 160-169.   | 2.6 | 11        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts. <i>Connective Tissue Research</i> , 2015, 56, 355-363.  | 2.3 | 10        |
| 74 | IDN 5390: a new concept in taxane development. <i>Anti-Cancer Drugs</i> , 2003, 14, 255-258.   | 1.4 | 9         |
| 75 | Snail levels control the migration mechanism of mesenchymal tumor cells. <i>Oncology Letters</i> , 2016, 12, 767-771.  | 1.8 | 9         |
| 76 | ADAMTS13 Deficiency Shortens the Life Span of Mice With Experimental Diabetes. <i>Diabetes</i> , 2018, 67, 2069-2083.  | 0.6 | 8         |
| 77 | Thrombospondins in bone remodeling and metastatic bone disease. <i>American Journal of Physiology - Cell Physiology</i> , 2020, 319, C980-C990.  | 4.6 | 5         |
| 78 | Human Immunodeficiency Virus-1 (HIV-1)-Tat Protein Promotes Migration of Acquired Immunodeficiency Syndrome-Related Lymphoma Cells and Enhances Their Adhesion to Endothelial Cells. <i>Blood</i> , 1999, 94, 1747-1754. | 1.4 | 5         |
| 79 | Microtubule Targeting Agents and the Tumor Vasculature. , 2008, , 519-530.   |     | 4         |
| 80 | The Macrophage Content of Tumors Is Unrelated to Levels of NK Cell-Mediated Resistance. <i>Journal of Leukocyte Biology</i> , 1986, 39, 113-119.   | 3.3 | 3         |
| 81 | Combination Therapy with Chemotherapy and VDAs. , 2010, , 77-93.   |     | 2         |
| 82 | Tumor vascular remodeling by thrombospondin-1 enhances drug delivery and antineoplastic activity. <i>Matrix Biology</i> , 2021, 103-104, 22-36.  | 3.6 | 2         |